<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741231</url>
  </required_header>
  <id_info>
    <org_study_id>IMMUNOPET ( 29BRC17.0253).</org_study_id>
    <nct_id>NCT03741231</nct_id>
  </id_info>
  <brief_title>18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy</brief_title>
  <acronym>IMMUNOPET</acronym>
  <official_title>18FluoroDeoxyGlucose-Positron Emission Tomography (PET) in Patients With Melanoma or Non Small Cell Lung Cancer Treated With Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung
      cancer treated by immunotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti
      PDL1) and performed18FDG PET

      Multicentric retrospective study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measure of progression free survival (obtained by the delay between the date of initiation of immunotherapy until the date of first documented progression disease in patients with melanoma or NSCLC treated by immunotherapy</measure>
    <time_frame>up to 50 months</time_frame>
    <description>From date of initiation of treatment until the date of first documented progression disease according to different criteria in interim PET/CT 1.
18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of overall survival (obtained by the delay between the date of initiation of immunotherapy until the date of death related to disease in patients with melanoma or NSCLC treated by immunotherapy</measure>
    <time_frame>up to 50 months</time_frame>
    <description>From date of initiation of treatment until the date of death related to disease according to different criteria in interim PET/CT 1.
18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study different criteria (RECIST, iRECIST, PERCIST and PECRIT) to predict PFS or OS</measure>
    <time_frame>up to 50 months</time_frame>
    <description>Interpretation according to 4 criteria to predict response to immunotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>study the potential correlation between PET data and clinicobiological data</measure>
    <time_frame>up to 50 months</time_frame>
    <description>correlation between adverse events (AE) due to immunotherapy described on PET data and AE detected on clinicobiological data</description>
  </secondary_outcome>
  <enrollment type="Actual">70</enrollment>
  <condition>Melanoma</condition>
  <condition>NSCLC</condition>
  <condition>Positron-Emission Tomography</condition>
  <condition>Immunotherapy</condition>
  <condition>18F-FDG</condition>
  <eligibility>
    <study_pop>
      <textblock>
        70 patients (50 patients with melanoma and 20 patients with NSCLC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients treated for melanoma or NSCLC with immunotherapy (anti CTLA4 or antiPDL1)

          -  patients treated in Brest, Morlaix, Landerneau hospital

          -  patients performed FDG PET

          -  no opposition to study

        Exclusion Criteria:

          -  age under 18 years old

          -  refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de LANDERNEAU</name>
      <address>
        <city>Landerneau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Morlaix</name>
      <address>
        <city>Morlaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>NSCLC</keyword>
  <keyword>FDG</keyword>
  <keyword>PET</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

